BioSpace News Archive

Daré Bioscience, Inc., a leader in women’s health innovation, announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will deliver a company presentation at the H.C. Wainwright BIOCONNECT 2022 Conference being held virtually January 10 – 13, 2022.

Adverum Biotechnologies, Inc. announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ADVM-062 (AAV.7m8-L-opsin).

AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today highlighted its recent progress and outlook for 2022.

Cardiff Oncology, Inc. announced that company management will present at the H.C. Wainwright BioConnect Virtual Conference, taking place January 10 – 13, 2022.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted four newly-hired employees inducement options to purchase an aggregate of 23,000 shares of KalVista common stock on January 3, 2022 as inducements material to each employee entering into employment with KalVista.

Seres Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference.

Funding Will Support Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Respiratory Infections in CF Patients.

Enanta Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference.

Precision BioSciences to Present at the 40th Annual J.P. Morgan Health Care Conference.

Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the first preclinical results of the use of Humacyte’s Human Acellular Vessel™ (HAV) in coronary artery bypass grafting (CABG) will be presented at the Advanced Therapies Week conference in Miami, Fla. at 9:20 a.m. EST on January 28, 2022.